Larimar Therapeutics Widens Loss as BLA Submission Begins
The biotechnology company reported a net loss of $32.8 million for the second quarter of 2026.
Larimar Therapeutics (LRMR) reported a net loss of $32.8 million, or $0.30 a share, for the second quarter of 2026. The loss increased from $26.2 million, or $0.41 a share, in the second quarter of 2025.
The biotech developer is currently transitioning toward commercialization, a shift reflected in rising operational costs. Research and development expenses rose to $28.0 million from $23.4 million in the prior-year period. This increase was due to a $2.2 million rise in process performance qualification and manufacturing, alongside $2.0 million in professional fees for clinical trials and BLA preparation.
General and administrative expenses increased to $6.4 million from $4.4 million in the second quarter of 2025. The rise was primarily due to accelerated commercial activities for a planned product launch.
In June 2026, the company initiated a rolling BLA submission with the first module submitted. Completion of the submission is expected in the second half of 2026. Larimar also released data from an open-label study in June 2026, which showed 100% of participants maintained skin FXN levels above asymptomatic carriers through 18 months and a 2.6-point benefit in mFARS at one year relative to the FACOMS reference population.
Some clinical and commercial timelines have shifted. Dosing of the first patient in the global confirmatory Phase 3 study is now expected in the third quarter of 2026, moving from the mid-2026 target stated in the prior quarter. The company also shifted its targeted US launch timing to mid-2027, compared to the first-half 2027 target stated in the fourth quarter 2025 release.
Cash, cash equivalents, and marketable securities decreased to $156.3 million as of June 30, 2026, from $200.4 million as of March 31, 2026. Despite the decrease in liquidity, the company extended its projected cash runway into the third quarter of 2027, compared to the second quarter of 2027 projected in the prior quarter.